Cancer News and Research

Latest Cancer News and Research

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

Lack of strong molecular 'glue' allows tumour cells to break away and spread

A remarkable discovery into how tumour cells invade normal tissue should lead to vital diagnostic tools and help develop strategies to stop the spread of cancer cells. A new study by scientists at the Montreal Neurological Institute and Hospital of McGill University reveals that the surface of aggressive tumour cells lack the strong molecular 'glue' responsible for binding normal cells together.

14 Dec 2010

Even small amount of alcohol increases chances of developing cancer

When raising your glass at this year's holiday toast, choose your beverage wisely, say experts at The University of Texas MD Anderson Cancer Center. If adults wish to drink alcohol, they should select drinks low in calories and alcohol content to limit cancer risk.

14 Dec 2010

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile.

14 Dec 2010

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics Inc. and UCB today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.

14 Dec 2010

Beta-catenin protein plays a key role in development of stem cells in acute leukaemia

Researchers at King's College London have discovered that leukaemic stem cells can be reversed to a pre-leukaemic stage by suppressing a protein called beta-catenin found in the blood.

14 Dec 2010

Reversible two-step binding mechanism to stop cancer cell growth

What makes cancer cells so dangerous is that they grow in an unregulated way and proliferate much faster than other cells. The proteasome, a large protein complex, plays a key role in this process: By breaking down used proteins for recycling, it clears the way for the next cycle.

14 Dec 2010

Osteoporosis drug reduces bone loss in oral cancer

A drug currently approved for osteoporosis treatment has been shown to reduce bone loss in a study of mice with oral cancer, suggesting it could serve as an important supplemental therapy in patients with head and neck cancers that erode bone.

14 Dec 2010

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

UCSF physicians are combating a devastating side effect of chemotherapy with an innovative new program -- "Hair to Stay" -- to evaluate devices that could reduce scalp hair loss in breast cancer patients.

14 Dec 2010

Novel labeling technique helps researchers to explore DNA chemical modification

Researchers at Emory University School of Medicine and the University of Chicago have developed a method for labeling and mapping a "sixth nucleotide," whose biological role scientists are only beginning to explore.

14 Dec 2010

ACCESS receives $6.7M NIH Clinical and Translational Science Award

Access Community Health Network (ACCESS) has received a $6.7 million Clinical and Translational Science Award grant from the National Institutes of Health (NIH) to construct a community-based research center. The goal of the center's research will be to engage the community and reduce racial and ethnic disparities in health care.

14 Dec 2010

FOXA1 gene controls oestrogen-fuelled growth of breast cancer cells

CANCER RESEARCH UK scientists have discovered that a single gene controls the oestrogen-fuelled growth of breast cancer cells, according to research published in Nature Genetics on Sunday.

14 Dec 2010

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

14 Dec 2010

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.

13 Dec 2010

Majority of brain tumor patients use alternative therapies

Many people with incurable brain tumors use alternative therapies, such as taking vitamins and homeopathy, in addition to their conventional treatments, according to a study published in the December 14, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology.

13 Dec 2010

Soda taxes – would they do any good?

According to new research from Duke-National University of Singapore (NUS) Graduate Medical School imposing higher taxes on sodas and other sweetened drinks would lead to only minimal weight loss among most people and would have no effect on weight among consumers in the highest and lowest income groups.

13 Dec 2010

South Korean FDA approves EDAP's new Sonolith i-move lithotripter

EDAP TMS SA, the global leader in therapeutic ultrasound, reported today the approval of its new lithotripter Sonolith i-move by South-Korean Food and Drug Administration (KFDA).

13 Dec 2010

CEL-SCI reports net income of $10.48M for fiscal 2010 vs. $40.9M loss for fiscal 2009

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2010.

13 Dec 2010

Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Cedarlane Laboratories of Burlington, ON, Canada, a leading supplier of Life Science research reagents in North America.

13 Dec 2010

Bionovo reports positive Menerba clinical program meeting with FDA

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of innovative treatments for women's health and cancer, today announced that it had received the minutes from the U.S. Food and Drug Administration's (FDA) Clinical Guidance meeting that took place on November 8, 2010. In that meeting, the FDA agreed with the Company's proposed overall clinical development plan.

13 Dec 2010